Skip to main content
OpenTrials
Completed

NCT Number: NCT02995915

Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking

Alcohol misuse and smoking constitute two of the three leading preventable causes of death in the United States. The purpose of this research study is to develop an intervention designed to help people stop drinking alcohol and stop smoking at the same time.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Duke University Medical Center

Durham, North Carolina, 27706, United States

About this study

Alcohol misuse and smoking constitute two of the three leading preventable causes of death in the United States. Reluctance to treat tobacco dependence among those with AUD is misguided as recent research suggests smoking cessation treatment can be effective, does not increase risk of relapse to alcohol, and may even improve rates of sobriety. There is strong evidence for the short-term efficacy for alcohol misuse and smoking of contingency management (CM). It is an intensive behavioral therapy that provides incentives (vouchers, money) to individuals misusing substances contingent upon objective evidence from drug use. Implementation of CM has been limited because of the need to verify abstinence multiple times daily using clinic based monitoring. The investigators recently developed a smart-phone application which allows a patient to video themselves several times daily while using a small CO monitor and to transmit the data to a secure server which has made the use of CM for outpatient smoking cessation portable and feasible. This mobile CM (mCM) approach paired with cognitive-behavioral counseling and pharmacological smoking cessation aids has been effective in reducing smoking.

Thus, the purpose of this project is to develop a combined alcohol and smoking mCM intervention. The intervention will be developed in two successive cohorts of five participants, who will provide information on treatment acceptability and feasibility. A third cohort of participants (n=45) will participate in a randomized clinical trials to further examine feasibility and efficacy. The long term goal is to develop mCM procedures that will be used as part of a multi-component intervention to concurrently and effectively treat both alcohol misuse and smoking. As part of this project, the investigators will develop a multi-component telehealth alcohol and smoking mCM intervention. It will include mCM, cognitive-behavioral phone counseling, and standard smoking cessation pharmacotherapy. The work proposed in these aims will provide the first step toward implementation of an innovative approach that builds upon the power of mHealth technology to reduce the prevalence of both alcohol misuse and smoking.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • currently meet criteria for DSM-5 mild to moderate alcohol use disorder (meeting 2-5 criteria for AUD)
  • have been engaging in hazardous drinking over the past month, defined as either exceeding a mean of 14 standard drinks/wk for men, 7 drinks/wk for women; or by consuming >5 on at least one occasion in the last month for men, >4 drinks on at least one occasion in the last month for women
  • currently smoke >10 cigarettes a day, and have smoked for at least one year
  • can speak and write fluent conversational English
  • are willing to make an attempt to quit both alcohol and smoking

Exclusion criteria

  • are expected to have unstable medication regimen during the study
  • are currently receiving non-study behavioral treatment for alcohol use disorder or smoking
  • have severe alcohol use disorder (meeting >6 criteria for AUD or having alcohol withdrawal symptom criterion)
  • have AUD that is in early remission, with no symptoms evident over the past month
  • have experienced myocardial infarction in past 6 months
  • contraindication to nicotine replacement therapy with no medical clearance to participate in the study
  • use other forms of nicotine such as cigars, pipes, or chewing tobacco
  • are currently pregnant
  • have a primary psychotic disorder or current manic episode
  • have had substance use disorder (other than alcohol or nicotine) in the preceding 3 months
  • are currently imprisoned or in psychiatric hospitalization

Treatment and study plan

Nicotine Replacement Therapy

Other

Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or nicotine lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings

Other names: nicotine gum, patch, inhaler, and/or lozenge

bupropion

Drug

All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.

Other names: Zyban

Cognitive Behavioral Treatment

Behavioral

Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.

Other names: CBT

Mobile Contingency Management

Behavioral

Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence.

Other names: mobile CM, mCM

Mobile Monitoring

Behavioral

Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence.

Primary outcomes

  1. Number of Participants Who Self-report Prolonged Abstinence From Smoking

    Time frame: 6 month follow-up

    Participants will be asked to report on smoking since two weeks past quit date

  2. Number of Participants Whose Prolonged Abstinence From Smoking is Bio-verified

    Time frame: 6 month follow-up

    Self-reported prolonged abstinence (primary outcome) will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence.

  3. Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use

    Time frame: 6 month follow-up

    Participants will be asked to report on alcohol use since two weeks past quit date

  4. Number of Participants Whose Prolonged Abstinence From Alcohol is Bio-verified

    Time frame: 6 month follow-up

    Self-reported prolonged abstinence will be verified by breathalyzer. Breathalyzer data will be collected from participants who self-report prolonged abstinence.

  5. Number of Participants Who Self-report Prolonged Dual Abstinence From Both Smoking and Alcohol

    Time frame: 6 month follow-up

    Participants will be asked to report on smoking and alcohol use since two weeks past quit date

  6. Number of Participants Whose Prolonged Dual Abstinence From Alcohol and Smoking is Bio-verified

    Time frame: 6 month follow-up

    Self-reported prolonged abstinence from smoking will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence.Self-reported prolonged abstinence will be verified by breathalyzer. Breathalyzer data will be collected from participants who self-report prolonged abstinence.

Secondary outcomes

  1. Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking

    Time frame: 6 month follow-up

    7-day point prevalence abstinence is defined as no smoking in the prior 7 days.

  2. Number of Participants Who Report 30 Day Point Prevalence Abstinence From Smoking

    Time frame: 6 month follow-up

    30-day point prevalence abstinence is defined as no smoking in the prior 30 days

  3. Change in the Proportion of Days in Which Consumed Alcohol Compared to Pre-quit Use

    Time frame: 6 month follow-up

    Participants will self-report number of days drank alcohol in the past 30 days and this will be compared to self-reported number of days drank alcohol in 30 days prior to quit.

  4. Change in the Number of Standard Alcoholic Beverages Consumed Per Week Compared to Pre-quit Use

    Time frame: 6 month follow-up

    Participants will self-report number of alcoholic beverages consumed in past 7 days and this will be compared to self-reported number of alcoholic beverages consumed in 7 days prior to quit.

  5. Change in the Number of Heavy Drinking Episodes Compared to Pre-quit Use

    Time frame: 6 month follow-up

    Participants will self-report number of heavy drinking episodes in the past 30 days and this will be compared to self-reported number of heavy drinking episodes in 30 days prior to quit.

  6. Number of Participants Who Are Able to Achieve Recommended Drinking Limits (i.e., Less Than or Equal to 14 Drinks Per Week and Fewer Than 5 Drinks Per Day for Men; Less Than or Equal to 7 Days Per Week and Less Than 4 Drinks Per Day for Women)

    Time frame: 6 month follow-up

    Participants will be asked to report on alcohol use in past week

  7. Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use

    Time frame: 6 week follow-up (i.e., end of treatment visit)

    Participants will be asked to report on alcohol use since two weeks past quit date

  8. Number of Participants Whose Prolonged Abstinence From Alcohol is Bio-verified

    Time frame: 6 week follow-up (i.e., end of treatment visit)

    Self-reported prolonged abstinence will be verified by breathalyzer. Breathalyzer data will be collected from participants who self-report prolonged abstinence.

  9. Change in Number of Average Cigarettes Smoked Per Day

    Time frame: 6 month follow-up

    Participants will self-report average number of cigarettes smoked in the past week and this will be compared to self-reported number of smoked in the week prior to quit.

  10. Change in the Proportion of Days in Which Smoked Compared to Pre-quit Use

    Time frame: 6 month follow-up

    Participants will self-report number of days smoked in the past 30 days and this will be compared to self-reported number of days smoked 30 days prior to quit.

  11. Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking

    Time frame: 6 week follow-up (i.e., end of treatment visit)

    Participants will be asked to report on smoking since two weeks past quit date

  12. Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking

    Time frame: 8 week follow-up (i.e., Session 7, end of monitoring visit)

    Participants will be asked to report on smoking since two weeks past quit date

  13. Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use

    Time frame: 8 week follow-up (i.e., Session 7, end of monitoring visit)

    Participants will be asked to report on alcohol use since two weeks past quit

  14. Number of Participants Who Self-report Prolonged Abstinence From Smoking

    Time frame: 6 week follow-up (i.e., end of treatment visit)

    Participants will be asked to report on alcohol use since two weeks past quit

  15. Number of Participants Who Self-report Prolonged Abstinence From Smoking

    Time frame: 8 week follow-up (i.e., Session 7, end of monitoring visit)

    Participants will be asked to report on alcohol use since two weeks past quit

  16. Number of Participants Who Self-report 30 Day Point Prevalence Abstinence From Smoking

    Time frame: 6 week follow-up (i.e., end of treatment visit)

    Participants will be asked to report on smoking since two weeks past quit date

  17. Number of Participants Who Self-report 30 Day Point Prevalence Abstinence From Smoking

    Time frame: 8 week follow-up (i.e., Session 7, end of monitoring visit)

    Participants will be asked to report on smoking since two weeks past quit date

  18. Number of Smoking Quit Attempts

    Time frame: 6 week follow-up (i.e., end of treatment visit)

    Participants will be asked to report the number of quit attempts made since quit date

  19. Number of Smoking Quit Attempts

    Time frame: 8 week follow-up (i.e., Session 7, end of monitoring visit)

    Participants will be asked to report the number of quit attempts made since quit date

  20. Number of Smoking Quit Attempts

    Time frame: 6-month follow-up

    Participants will be asked to report the number of quit attempts made since quit date

Sponsors and collaborators

Lead sponsor

Duke University

Other

Registry information

Important dates

Study start
2016
Primary completion
2020
Study completion
2020
First posted
Dec 19, 2016
Registry last updated
Apr 28, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.